173
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Overexpression of TIGAR and HO-1 in peripheral blood mononuclear cells (PBMCs) of breast cancer patients treated with radiotherapy

ORCID Icon, , ORCID Icon, & ORCID Icon
Pages 1551-1558 | Received 07 Jan 2022, Accepted 19 Mar 2022, Published online: 01 Jun 2022

References

  • Acevedo C, Amaya C, López-Guerra J-L. 2014. Rare breast tumors: review of the literature. Rep Pract Oncol Radiother. 19(4):267–274.
  • Arjmandi MK, Moslemi D, Zarrini AS, Gorji ME, Mosapour A, Haghhaghighi A, Halalkhor S, Bijani A, Parsian H. 2016. Pre and post radiotherapy serum oxidant/antioxidant status in breast cancer patients: impact of age, BMI and clinical stage of the disease. Rep Pract Oncol Radiother. 21(3):141–148.
  • Arnandis T, Monteiro P, Adams SD, Bridgeman VL, Rajeeve V, Gadaleta E, Marzec J, Chelala C, Malanchi I, Cutillas PR, et al. 2018. Oxidative stress in cells with extra centrosomes drives non-cell-autonomous invasion. Dev Cell. 47(4):409–424. e409.
  • Baskar R, Lee KA, Yeo R, Yeoh K-W. 2012. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 9(3):193–199.
  • Benzie IF, Strain JJ. 1996. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem. 239(1):70–76.
  • DeSantis CE, Miller KD, Dale W, Mohile SG, Cohen HJ, Leach CR, Sauer AG, Jemal A, Siegel RL. 2019. Cancer statistics for adults aged 85 years and older, 2019. CA A Cancer J Clin. 69(6):452–467.
  • Duvigneau JC, Piskernik C, Haindl S, Kloesch B, Hartl RT, Hüttemann M, Lee I, Ebel T, Moldzio R, Gemeiner M, et al. 2008. A novel endotoxin-induced pathway: upregulation of heme oxygenase 1, accumulation of free iron, and free iron-mediated mitochondrial dysfunction. Lab Invest. 88(1):70–77.
  • Gandini NA, Alonso EN, Fermento ME, Mascaró M, Abba MC, Coló GP, Arévalo J, Ferronato MJ, Guevara JA, Núñez M, et al. 2019. Heme oxygenase-1 has an antitumor role in breast cancer. Antioxid Redox Signal. 30(18):2030–2049.
  • Geng J, Yuan X, Wei M, Wu J, Qin Z-H. 2018. The diverse role of TIGAR in cellular homeostasis and cancer. Free Radic Res. 52(11-12):1240–1249.
  • Haussmann J, Corradini S, Nestle-Kraemling C, Bölke E, Njanang FJD, Tamaskovics B, Orth K, Ruckhaeberle E, Fehm T, Mohrmann S, et al. 2020. Recent advances in radiotherapy of breast cancer. Radiat Oncol. 15(1):1–10.
  • Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, et al. 2013. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 14(11):1086–1094.
  • Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker‐Prietz A, Iacobuzio‐Donahue CA, Griffith ME, Pawlik TM, Pai JS, et al. 2015. Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 121(7):1128–1137.
  • Jiang L-B, Cao L, Ma Y-Q, Chen Q, Liang Y, Yuan F-L, Li X-L, Dong J, Chen N. 2018. TIGAR mediates the inhibitory role of hypoxia on ROS production and apoptosis in rat nucleus pulposus cells. Osteoarthritis Cartilage. 26(1):138–148.
  • Klein J, Tran W, Watkins E, Vesprini D, Wright FC, Hong NJL, Ghandi S, Kiss A, Czarnota GJ. 2019. Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis. BMC Cancer. 19(1):1–11.
  • Kusano C, Ferrari B. 2008. Total antioxidant capacity: a biomarker in biomedical and nutritional studies. J Cell Mol Biol. 7(1):1–15.
  • Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyürek LM, Lindahl P, Nilsson J, et al. 2015. Antioxidants can increase melanoma metastasis in mice. Sci Transl Med. 7(308):308re308–308re308.
  • Lin P-H, Chiang M-T, Chau L-Y. 2008. Ubiquitin–proteasome system mediates heme oxygenase-1 degradation through endoplasmic reticulum-associated degradation pathway. Biochim Biophys Acta Mol Cell Res. 1783(10):1826–1834.
  • Maines MD. 1988. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2(10):2557–2568.
  • Marín A, Martín M, Liñán O, Alvarenga F, López M, Fernández L, Büchser D, Cerezo L. 2015. Bystander effects and radiotherapy. Rep Pract Oncol Radiother. 20(1):12–21.
  • Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko Y-H, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, et al. 2011. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther. 12(10):924–938.
  • Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, et al. 2010. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle. 9(17):3515–3533.
  • O’Halloran N, McVeigh T, Martin J, Keane M, Lowery A, Kerin M. 2019. Neoadjuvant chemoradiation and breast reconstruction: the potential for improved outcomes in the treatment of breast cancer. Ir J Med Sci. 188(1):75–83.
  • Ollinger R, Kogler P, Troppmair J, Hermann M, Wurm M, Drasche A, Königsrainer I, Amberger A, Weiss H, Ofner D, et al. 2007. Bilirubin inhibits tumor cell growth via activation of ERK. Cell Cycle. 6(24):3078–3085.
  • Peng Y-F, Goyal H, Xu G-D. 2017. Serum bilirubin has an important role in multiple clinical applications. J Lab Precis Med. 2(82):82–82.
  • Perez M, Schootman M, Hall L, Jeffe D. 2017. Accelerated partial breast irradiation compared with whole breast radiation therapy: a breast cancer cohort study measuring change in radiation side-effects severity and quality of life. Breast Cancer Res Treat. 162(2):329–342.
  • Plym A, Johansson AL, Bower H, Wennstig A-K, Fredriksson I, Ahlgren J, Lambe M. 2020. Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study. Breast Cancer Res Treat. 182(3):699–707.
  • Rahimi-Madiseh M, Heidarian E, Kheiri S, Rafieian-Kopaei M. 2017. Effect of hydroalcoholic Allium ampeloprasum extract on oxidative stress, diabetes mellitus and dyslipidemia in alloxan-induced diabetic rats. Biomed Pharmacother. 86:363–367.
  • Ryter SW, Tyrrell RM. 2000. The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties . Free Radic Biol Med. 28(2):289–309.
  • Saretzki G. 2010. Cellular senescence in the development and treatment of cancer. Curr Pharm Des. 16(1):79–100.
  • Seghatoleslam A, Nikseresht M, Shafiee SM, Monabati A, Namavari MM, Talei A, Safaei A, Owji AA. 2012. Expression of the novel human gene, UBE2Q1, in breast tumors. Mol Biol Rep. 39(5):5135–5141.
  • Shi L, Fang J. 2008. Implication of heme oxygenase-1 in the sensitivity of nasopharyngeal carcinomas to radiotherapy. J Exp Clin Cancer Res. 27(1):13–15.
  • Sisakht M, Darabian M, Mahmoodzadeh A, Bazi A, Shafiee SM, Mokarram P, Khoshdel Z. 2020. The role of radiation induced oxidative stress as a regulator of radio-adaptive responses. Int J Radiat Biol. 96(5):561–576.
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 71(3):209–249.
  • ten Kate M, Van Der Wal J, Sluiter W, Hofland L, Jeekel J, Sonneveld P, van Eijck C. 2006. The role of superoxide anions in the development of distant tumour recurrence. Br J Cancer. 95(11):1497–1503.
  • Ulmer A, Scholz W, Ernst M, Brandt E, Flad H-D. 1984. Isolation and subfractionation of human peripheral blood mononuclear cells (PBMC) by density gradient centrifugation on Percoll. Immunobiology. 166(3):238–250.
  • Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, Garber JE, Hofstatter EW, Khan SA, et al. 2019. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 37(33):3152–3165.
  • Waks AG, Winer EP. 2019. Breast cancer treatment: a review. JAMA. 321(3):288–300.
  • Was H, Dulak J, Jozkowicz A. 2010. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets. 11(12):1551–1570.
  • Waza AA, Hamid Z, Ali S, Bhat SA, Bhat MA. 2018. A review on heme oxygenase-1 induction: is it a necessary evil. Inflamm Res. 67(7):579–588.
  • Whelan TJ, Pignol J-P, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, et al. 2010. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 362(6):513–520.
  • Wiel C, Le Gal K, Ibrahim MX, Jahangir CA, Kashif M, Yao H, Ziegler DV, Xu X, Ghosh T, Mondal T, et al. 2019. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell. 178(2):330–345. e322.
  • Zhang Y-l, Li X-b, Hou Y-x, Fang N-z, You J-c, Zhou Q-h. 2017. The lncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung cancer. Acta Pharmacol Sin. 38(3):371–381.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.